Global biopharmaceutical company developing breakthrough treatments for ophthalmic and neuro-ophthalmic conditions.
About
Oculis is a global biopharmaceutical company (Nasdaq: OCS) focused on developing treatments for ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. The company's proprietary OPTIREACH® formulation technology enables eye drops to effectively reach the back of the eye. Its late-stage clinical pipeline includes Privosegtor (FDA Breakthrough Therapy Designation for optic neuritis), OCS-01 in pivotal studies for diabetic macular edema, and Licaminlimab for dry eye disease.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Oculis Pharmaceuticals do?
Oculis is a global biopharmaceutical company (Nasdaq: OCS) focused on developing treatments for ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. The company's proprietary OPTIREACH® formulation technology enables eye drops to effectively reach the back of the eye. Its late-stage clinical pipeline includes Privosegtor (FDA Breakthrough Therapy Designation for optic neuritis), OCS-01 in pivotal studies for diabetic macular edema, and Licaminlimab for dry eye disease…
Where is Oculis Pharmaceuticals headquartered?
Oculis Pharmaceuticals is headquartered in Zug, Switzerland.
When was Oculis Pharmaceuticals founded?
Oculis Pharmaceuticals was founded in 2017.
What industry does Oculis Pharmaceuticals operate in?
Oculis Pharmaceuticals operates in Biotechnology, Pharmaceuticals, Ophthalmology, Drug Development, HealthTech, Biopharmaceuticals.